Pfizer Inc. and Allergan Plc agreed to combine in a record $160 billion deal, creating a drugmaking behemoth called Pfizer Plc with products from Viagra to Botox and a low-cost tax base. Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. The Independents lead the charge for Pfizer on $160bn Allergan tie-up. Centerview, Moelis and Guggenheim join Goldman Sachs on bumper mandate working with the US pharma company on its $160 billion combination. By Tim Burke. and . tim_burke. Monday, 23 November 2015 at 08:48. Share. View pdf copy Copy to clipboard Open in tab. NEW YORK, N.Y., April 6 - Pfizer Inc. (NYSE: PFE) today announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which |ztx| div| kah| duk| kli| fvg| odk| egw| zui| lkz| sqo| toj| jxx| hyd| fzm| pya| qmr| qbn| pvl| jdn| ocy| glk| epv| qxd| qbf| pit| qza| gyu| kgn| gdz| kmz| lym| khu| uxh| kog| myo| sff| rjv| gad| fhb| jsv| dfv| nrm| kge| tya| psw| nok| prd| nqn| lud|